Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.
about
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyondThe gap between policy and practice: a systematic review of patient-centred care interventions in chronic heart failureCorrelation between brain natriuretic peptide levels and the prognosis of patients with left ventricular diastolic dysfunctionAdult heart transplant: indications and outcomesAdvanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations.Prognostic value of brain natriuretic peptide in patients with heart failure and reserved left ventricular systolic function.Improving care for people with heart failure in Uganda: serial in-depth interviews with patients' and their health care professionals.Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study.Improvement of left ventricular function under cardiac resynchronization therapy goes along with a reduced incidence of ventricular arrhythmia.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with theImpact of comorbidity on mortality among older persons with advanced heart failure.Clinical value of plasma B-type natriuretic peptide assay in pediatric pneumonia accompanied by heart failurePalliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and designThe cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failurePhysical and psychological symptom profiling and event-free survival in adults with moderate to advanced heart failure.Evolvement of left ventricular assist device: the implications on heart failure managementMolecular risk stratification in advanced heart failure patients.Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study.Who has advanced heart failure?: definition and epidemiology.Background and design of the profiling biobehavioral responses to mechanical support in advanced heart failure study.Decision making in advanced heart failure: a scientific statement from the American Heart AssociationForecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.Are scores useful in advanced heart failure?Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure.Challenges in advanced chronic heart failure: drug therapy.Can we improve the treatment of congestion in heart failure?Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents.Narrative review: the management of acute decompensated heart failure.Effective communication and ethical consent in decisions related to ICDs.Biomarkers in advanced heart failure: diagnostic and therapeutic insights.Renal function in advanced heart failure.Primary care patients with heart failure in the last year of their life.Contemporary management and research directions in advanced heart failure: where are we going?Heart transplantation in adults with end-stage congenital heart disease.Past and present of cardiocirculatory assist devices: a comprehensive critical review.Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods.Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review.Hold or fold--proteins in advanced heart failure and myocardial recovery.Therapeutic adjustments in stage D heart failure: challenges and strategies.
P2860
Q24645066-9EEB9CD9-5702-4BDD-96B5-3BB476E435E8Q26782388-146B096E-DD70-4760-8B62-91199891A636Q28601952-CEE69C53-AF67-4E47-89FB-832E7B58A3EEQ28654524-ECCD851E-67B6-48BB-B506-C65ABCBF43AEQ30394479-FD58B7F4-3F80-4F13-8054-9D1C35B42EEDQ33706264-E057ECA7-7841-4E85-B1EA-AB4641CAA0BAQ33730195-EE403491-43F9-44BE-821E-DA3DAB9F9EF1Q34148325-FB20FF1A-41E1-40BD-944A-4C0C3D038BCFQ34477559-5A9A80FE-4425-465E-81F2-F67B87351376Q34830023-D6CB19E4-A392-461D-B55C-FD5825741FBEQ35888142-50D11379-16B1-4014-9D53-BEBEF6B4D122Q36334557-EC975983-272A-4567-B46D-A5776473F718Q36894841-2AFCBDDD-8C46-4EF1-A23E-D66AB04A26AFQ37091016-A60014BD-54B4-44C0-BC41-C7225B3E3844Q37146882-4230717E-9DA4-418E-B57D-BACDBDD6C582Q37174283-7BCFE96F-9C68-4BBB-A300-C0E685233843Q37310977-79D03B8B-AE35-4E78-A86E-E27AB9366942Q37314355-8E27B35E-F801-4D22-B9B8-4F2E1201CF6CQ37379777-C787932F-DEE5-4D1F-8EF4-5B206DCCD6D6Q37452892-EEE56AAC-EFBC-46C9-9793-BD5D62A25F82Q37486284-C6A39E6C-4F3F-4463-AF6D-C43570D4010CQ37538031-100DC1F0-BBF7-483E-BD72-385A685211BFQ37578565-AF5A3D83-B603-498E-BE0F-12569EF8D6B9Q37607413-85BDB449-7B89-46CD-A210-A128D5338350Q37608608-7BFBD4BB-C19C-4617-BE82-0A7AF9D2DC5EQ37845856-9E78E8E4-74BB-4CBD-BBB6-78D22271F528Q37858515-C8223EE7-6682-4D91-A75E-3C64C9FBAB40Q37880500-5A10399B-A8CC-42B0-90A3-89AE5A33A07BQ37905530-8AE1BED1-0522-4AD7-93C3-D63F26D1250DQ37905948-C80C185E-B2CB-43B2-B601-174627EF5C72Q37905951-FA224D2D-0A7E-46FB-BAC3-E6CF6463C4FCQ37910639-417F10D4-AE6D-426E-A46C-42B314D85956Q37929868-3D888F49-2C9C-4FC2-9EF3-1A5A28302191Q37993155-4B0A86C2-D7C3-4747-85E8-59FDC00684DEQ38076112-EDC895AC-71A4-459A-BC23-FE775927A1BDQ38173852-299509E0-2BC9-4D26-89D4-3EFBDF3A6720Q38222335-1623B81A-C20F-4A9A-BC4F-07DDA7970968Q38232810-76B25B5E-15F5-4306-A160-DF3DE5B42A83Q38261514-DDF0C835-DE11-430D-93CD-E8993CD40DA7Q38267665-0A6F90C9-49A9-4389-987F-7E48A739CB02
P2860
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Advanced chronic heart failure ...... uropean Society of Cardiology.
@ast
Advanced chronic heart failure ...... uropean Society of Cardiology.
@en
type
label
Advanced chronic heart failure ...... uropean Society of Cardiology.
@ast
Advanced chronic heart failure ...... uropean Society of Cardiology.
@en
prefLabel
Advanced chronic heart failure ...... uropean Society of Cardiology.
@ast
Advanced chronic heart failure ...... uropean Society of Cardiology.
@en
P2093
P2860
P50
P1476
Advanced chronic heart failure ...... uropean Society of Cardiology.
@en
P2093
Alan G Fraser
Antonello Gavazzi
Antonis Pitsis
Claes-Hakan Bergh
Dirk Brutsaert
Heart Failure Association of the European Society of Cardiology
Henry Dargie
John J V McMurray
Michael Böhm
Paul Mohacsi
P2860
P304
P356
10.1016/J.EJHEART.2007.04.003
P577
2007-05-03T00:00:00Z